5am Venture Management is an investment fund managing more than $447 billion ran by Paul Stone. There are currently 28 companies in Mr. Stone’s portfolio. The largest investments include Skye Bioscience Inc and Entrada Therapeutics Inc, together worth $144 billion.
As of 7th August 2024, 5am Venture Management’s top holding is 10,179,505 shares of Skye Bioscience Inc currently worth over $81.5 billion and making up 18.2% of the portfolio value.
In addition, the fund holds 4,408,379 shares of Entrada Therapeutics Inc worth $62.8 billion.
The third-largest holding is Enliven Therapeutics Inc worth $61 billion and the next is Dianthus Therapeutics Inc worth $31.9 billion, with 1,232,965 shares owned.
Currently, 5am Venture Management's portfolio is worth at least $447 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The 5am Venture Management office and employees reside in San Francisco, California. According to the last 13-F report filed with the SEC, Paul Stone serves as the Partner and Chief Legal Officer at 5am Venture Management.
In the most recent 13F filing, 5am Venture Management revealed that it had opened a new position in
Skye Bioscience Inc and bought 10,179,505 shares worth $81.5 billion.
The investment fund also strengthened its position in Pharvaris N V by buying
210,000 additional shares.
This makes their stake in Pharvaris N V total 797,600 shares worth $15 billion.
On the other hand, there are companies that 5am Venture Management is getting rid of from its portfolio.
5am Venture Management closed its position in Cincor Pharma Inc on 14th August 2024.
It sold the previously owned 4,937,646 shares for $162 million.
Paul Stone also disclosed a decreased stake in scPharmaceuticals Inc by 0.6%.
This leaves the value of the investment at $5.22 billion and 1,200,647 shares.
The two most similar investment funds to 5am Venture Management are Dechtman Wealth Management and Jackson Hole Capital Partners. They manage $447 billion and $447 billion respectively.
5am Venture Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 19.4% of
the total portfolio value.
The fund focuses on investments in the United States as
39.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
11% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $589 million.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Skye Bioscience Inc |
Opened
10,179,505
|
$81,537,835,000 | 18.24% |
| Entrada Therapeutics Inc |
No change
4,408,379
|
$62,819,401,000 | 14.05% |
| Enliven Therapeutics Inc |
Opened
2,610,875
|
$61,016,149,000 | 13.65% |
| Dianthus Therapeutics Inc |
Opened
1,232,965
|
$31,909,134,000 | 7.14% |
| Celldex Therapeutics Inc. |
Opened
497,270
|
$18,403,963,000 | 4.12% |
| Biohaven Ltd |
Opened
469,972
|
$16,312,728,000 | 3.65% |
| Tyra Biosciences Inc |
Opened
939,298
|
$15,019,375,000 | 3.36% |
| Pharvaris N V |
35.74%
797,600
|
$14,994,880,000 | 3.35% |
| Praxis Precision Medicines I |
Opened
340,000
|
$14,062,400,000 | 3.15% |
| Erasca Inc |
Opened
5,405,404
|
$12,756,753,000 | 2.85% |
| Viking Therapeutics Inc |
Opened
237,560
|
$12,593,056,000 | 2.82% |
| Moonlake Immunotherapeutics |
Opened
282,313
|
$12,413,303,000 | 2.78% |
| Centessa Pharmaceuticals Plc |
Opened
1,245,000
|
$11,242,350,000 | 2.51% |
| Tectonic Therapeutic Inc |
Opened
646,524
|
$10,648,250,000 | 2.38% |
| Viridian Therapeutics Inc |
51.91%
736,595
|
$9,583,101,000 | 2.14% |
| Silence Therapeutics plc |
Opened
476,200
|
$9,047,800,000 | 2.02% |
| AnaptysBio Inc |
Opened
357,733
|
$8,964,789,000 | 2.01% |
| Gh Research Plc |
Opened
572,665
|
$6,677,274,000 | 1.49% |
| Cogent Biosciences, Inc. |
No change
790,440
|
$6,663,409,000 | 1.49% |
| Vor Biopharma Inc |
No change
6,361,723
|
$6,361,723,000 | 1.42% |
| scPharmaceuticals Inc |
64.00%
1,200,647
|
$5,222,814,000 | 1.17% |
| Rallybio Corp |
2.68%
3,630,724
|
$4,865,170,000 | 1.09% |
| Q32 Bio Inc |
Opened
251,994
|
$4,523,292,000 | 1.01% |
| Adverum Biotechnologies Inc |
Opened
541,666
|
$3,715,829,000 | 0.83% |
| Mersana Therapeutics Inc |
Opened
1,305,000
|
$2,623,050,000 | 0.59% |
| Zentalis Pharmaceuticals, Llc |
Opened
490,000
|
$2,004,100,000 | 0.45% |
| Cidara Therapeutics Inc |
Opened
56,725
|
$677,297,000 | 0.15% |
| EyePoint Pharmaceuticals Inc |
Opened
50,000
|
$435,000,000 | 0.10% |
| Cincor Pharma Inc |
Closed
4,937,646
|
$162,054,000 | |
| Pear Therapeutics Inc |
Closed
16,903,603
|
$34,483,000 | |
| Akouos, Inc. |
Closed
4,135,784
|
$27,958,000 | |
| IDEAYA Biosciences, Inc. |
Closed
1,196,298
|
$17,849,000 | |
| Arvinas Inc |
Closed
400,000
|
$17,796,000 | |
| Crinetics Pharmaceuticals In |
Closed
862,286
|
$16,935,000 | |
| Impel Neuropharma Inc |
Closed
2,884,791
|
$14,049,000 | |
| IVERIC bio Inc |
Closed
508,847
|
$9,129,000 | |
| Homology Medicines Inc |
Closed
4,535,919
|
$7,303,000 | |
| Avidity Biosciences, Inc. |
Closed
390,555
|
$6,378,000 | |
| Janux Therapeutics Inc |
Closed
446,266
|
$6,042,000 | |
| 5 01 Acquisition Corp |
Closed
365,126
|
$3,651,000 | |
| Gemini Therapeutics Inc |
Closed
524,500
|
$860,000 | |
| Cidara Therapeutics Inc |
Closed
1,134,511
|
$712,000 | |
| No transactions found | |||
| Showing first 500 out of 42 holdings | |||